David Hirsch

Dr. Hirsch is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Ventures, where he worked in the life sciences practice. Prior to Pequot Ventures, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. Dr. Hirsch currently serves on the boards of Amunix Pharmaceuticals, Molecular Templates (MTEM), Poseida Therapeutics (PSTX), Rapid Micro Biosystems, Tricida (TCDA) and Velicept. Previous boards include Civitas Therapeutics (acquired by Acorda), Collegium Pharmaceutical (COLL), Inflazome (acquired by Roche), Precision Therapeutics and Zavante Therapeutics (acquired by Nabriva). Dr. Hirsch also led Longitude Capital’s investments in Amarin (AMRN) and Cadence Pharmaceuticals (CADX). Dr. Hirsch holds a Ph.D. in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a B.A. in Biology from The Johns Hopkins University.